CoChat

Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer

Open access
Carabet, Lavinia A., Lallous, Nada, Leblanc, Eric, Ban, Fuqiang, Morin, Helene, Lawn, Sam, Ghaidi, Fariba, Lee, Joseph, Mills, Ian G., Gleave, Martin E., Rennie, Paul S., Cherkasov, Artem · 2018 · European Journal of Medicinal Chemistry
Cited by 52

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

While Myc is an essential regulator of growth in normal cells, it is also frequently associated with cancer progression, therapy-resistance and lethal outcomes in most human cancers. In prostate cancer (PCa), Myc transcription factors are implicated in the pathogenesis and progression of the full spectrum of PCa, from adenocarcinoma to advanced castration-resistant and neuroendocrine phenotypes. Though a high-value therapeutic target, clinically approved anti-Myc drugs have yet to be discovered. To elicit its oncogenic effects, Myc must form a heterodimer with its partner Max, which together bind DNA and activate transcription of a spectrum of target genes that promote cell growth, proliferation, metabolism, and apoptosis while blocking differentiation. In this study, we identified a binding site on the DNA-binding domain of the structurally ordered Myc-Max complex and employed a computer-aided rational drug discovery approach to identify small molecules that effectively inhibit Myc-Max functionality. A large-scale virtual screening protocol implementing structure-based methodologies was utilized to select a set of top-ranked compounds that were subsequently evaluated experimentally and characterized mechanistically for their ability to inhibit Myc-Max transcriptional activity and subsequent downstream functions, to reduce viability in PCa cell lines, disrupt protein-DNA interactions and to induce apoptosis as their mechanism of action. Among compounds identified that effectively inhibit Myc-Max activity with low to mid-micromolar range potency and no or minimal generic cytotoxicity, VPC-70067, a close analog of the previously identified Myc inhibitor 10058-F4, served as proof-of-concept that our in silico drug discovery strategy performed as expected. Compound VPC-70063, of a chemically different scaffold, was the best performer in a panel of in vitro assays, and the forerunner for future hit-to-lead optimization efforts. These findings lay a foundation for developing more potent, specific and clinically optimized Myc-Max inhibitors that may serve as promising therapeutics, alone or in combination with current anti-cancer treatments, for treatment of specific phenotypes or heterogeneous tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejmech.2018.09.023

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 52

Metadata

Authors
Carabet, L. A., Lallous, N., Leblanc, E., Ban, F., Morin, H., Lawn, S., Ghaidi, F., Lee, J., Mills, I. G., Gleave, M. E., Rennie, P. S., & Cherkasov, A.
Venue
European Journal of Medicinal Chemistry
Publisher
Elsevier BV
Published
2018-12
Volume
160
Pages
108-119
ISSN
0223-5234 (ISSN-L)
OpenAlex
W2891421253
Cited by
52
References
10
FWCI
4.26
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. https://app.cochat.ai/papers/10.1016/j.ejmech.2018.09.023
The paper
Carabet, L. A., Lallous, N., Leblanc, E., Ban, F., Morin, H., Lawn, S., Ghaidi, F., Lee, J., Mills, I. G., Gleave, M. E., Rennie, P. S., & Cherkasov, A. (2018). Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. European Journal of Medicinal Chemistry. https://doi.org/10.1016/j.ejmech.2018.09.023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.